Holen Sie sich die Stockscreener-App
0.6748
1.92%
0.0127
Handel nachbörslich:
.67
-0.0048
-0.71%
Schlusskurs vom Vortag:
$0.6621
Offen:
$0.67
24-Stunden-Volumen:
968.69K
Relative Volume:
0.19
Marktkapitalisierung:
$20.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.77M
KGV:
-0.0441
EPS:
-15.2954
Netto-Cashflow:
$-24.23M
1W Leistung:
+2.91%
1M Leistung:
+22.67%
6M Leistung:
-46.87%
1J Leistung:
-71.29%
1-Tages-Spanne:
$0.6435
$0.695
1-Wochen-Bereich:
$0.6208
$0.695
52-Wochen-Spanne:
$0.25
$3.6499
Moleculin Biotech Inc Stock (MBRX) Company Profile
Firmenname
Moleculin Biotech Inc
Sektor
Branche
Telefon
713-300-5160
Adresse
5300 MEMORIAL DRIVE, HOUSTON, TX
Vergleichen Sie MBRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.6748 | 18.79M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-09 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-12 | Herabstufung | Maxim Group | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
Moleculin Biotech Inc Aktie (MBRX) Neueste Nachrichten
Moleculin Reports Second Quarter 2025 Financial Results and Highlights - GlobeNewswire
Moleculin's Cancer Drug Trial Grows Globally as Critical Data Readout Approaches in 2025 - Stock Titan
How liquid is Moleculin Biotech Inc. stockJuly 2025 Final Week & Verified Chart Pattern Signals - newsyoung.net
Moleculin Biotech MBRX 2025Q2 Earnings Preview Upside Potential Driven by Strategic Developments - AInvest
Moleculin Biotech shares rise 3.66% premarket after unveiling promising preclinical data for Annamycin. - AInvest
Moleculin Biotech shares fall 5.11% intraday despite promising preclinical data for Annamycin. - AInvest
Moleculin Biotech announces preclinical data of annamycin in liver cancer - TipRanks
Moleculin Biotech Reveals Promising Preclinical Data for Annamycin - TipRanks
Moleculin Biotech Highlights Annamycin's Potential Against Liver Cancers with Promising Preclinical Data - Quiver Quantitative
Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment - GlobeNewswire
Revolutionary Cancer Treatment: Moleculin's Annamycin Targets 3 Types of Liver Cancer Without Heart Risks - Stock Titan
What is Moleculin Biotech Inc. company’s growth strategyMaximize returns with expert trading insights - Jammu Links News
Is Moleculin Biotech Inc. a good long term investmentAchieve unparalleled market performance - Jammu Links News
How does Moleculin Biotech Inc. compare to its industry peersInvest smarter with high-probability setups - Jammu Links News
Is it the right time to buy Moleculin Biotech Inc. stockUnlock real-time trading signals for gains - Jammu Links News
What makes Moleculin Biotech Inc. stock price move sharplyBuild a diversified portfolio for steady profits - Jammu Links News
Moleculin Biotech Releases Corporate Presentation Update - AInvest
What are the latest earnings results for Moleculin Biotech Inc.Capitalize on emerging trends for profits - Jammu Links News
What catalysts could drive Moleculin Biotech Inc. stock higher in 2025Robust financial gains - Jammu Links News
How volatile is Moleculin Biotech Inc. stock compared to the marketFree Stock Market Forecast Reports - Jammu Links News
How strong is Moleculin Biotech Inc. company’s balance sheetFree Stock Market Mentorship - Jammu Links News
Moleculin receives notice of intent to grant new European patent for Annamycin - MSN
Moleculin Biotech Inc. Ranks High in Smart Money TrackerROI Driven Equity Selection With Safety Emphasized - metal.it
What Caused the Sharp Drop in Moleculin Biotech (MBRX.O)? - AInvest
Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin - GlobeNewswire
Will Moleculin Biotech Inc. Stock Benefit from AI and Green Energy TrendsAccurate Buy Point for Momentum Stocks Detected - metal.it
Moleculin receives European patent notice for cancer drug Annamycin By Investing.com - Investing.com Nigeria
Moleculin receives European patent notice for cancer drug Annamycin - Investing.com
Moleculin Biotech Secures European Patent for Annamycin - TipRanks
Moleculin Biotech, Inc. Receives Notice of Intent to Grant European Patent for Annamycin, Strengthening Market Position in Oncology - Quiver Quantitative
Breakthrough Cancer Drug Patent: Moleculin's Non-Cardiotoxic Treatment Gains EU Protection Until 2040 - Stock Titan
Why Did Moleculin Biotech Inc. (MBRX) Soar 10.08%? - AInvest
Statistical indicators supporting Moleculin Biotech Inc.’s strengthIntraday Trend Analysis for Fast Gains Released - metal.it
Why Did Moleculin Biotech Inc. (MBRX) Soar 11.82%? - AInvest
why MBRX is up afterhours - AInvest
Why Moleculin Biotech Inc. stock attracts strong analyst attentionValue Investing Picks With Stability Outlined - metal.it
What are analysts’ price targets for Moleculin Biotech Inc. in the next 12 monthsConsistently exceptional gains - Jammu Links News
When is Moleculin Biotech Inc. stock expected to show significant growthAchieve breakthrough gains with smart trades - Jammu Links News
whats better mbrx or pstv - AInvest
Finanzdaten der Moleculin Biotech Inc-Aktie (MBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Moleculin Biotech Inc-Aktie (MBRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KLEMP WALTER V | CEO and President |
Jun 23 '25 |
Buy |
0.37 |
675,675 |
250,000 |
743,607 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):